Christof von Kalle has been Director of the Department of Translational Oncology at NCT and at DKFZ since July 2005, and chairpersons the NCT Board of Directors. He coordinates overall NCT activities with the primary goal of facilitating excellence in translational and clinical research at DKFZ and the Heidelberg University Hospital.
The NCT Precision Oncology Program (NCT POP) combines molecular diagnostics, innovative therapeutics development and interdisciplinary patient care and prevention to define molecularly stratified patient cohorts and hypothesis driven treatments.
As physician scientist with a clinical background in hematology/oncology, he is an internationally renowned scientific leader in;
- Stem cell research, mutation analysis and gene transfer.
- Scientific background in treatment of rare genetic diseases.
- Research on gene therapy induced mutations in humans.
- Treating cancer as multiple molecular diseases in one cell.